IT1397011B1 - Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. - Google Patents
Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.Info
- Publication number
- IT1397011B1 IT1397011B1 ITTO2009A000782A ITTO20090782A IT1397011B1 IT 1397011 B1 IT1397011 B1 IT 1397011B1 IT TO2009A000782 A ITTO2009A000782 A IT TO2009A000782A IT TO20090782 A ITTO20090782 A IT TO20090782A IT 1397011 B1 IT1397011 B1 IT 1397011B1
- Authority
- IT
- Italy
- Prior art keywords
- vehiculation
- oligonucleotids
- nanoparticle
- medication
- therapeutic
- Prior art date
Links
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 title 1
- 239000011258 core-shell material Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000004744 fabric Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2009A000782A IT1397011B1 (it) | 2009-10-14 | 2009-10-14 | Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. |
| EP10771208.5A EP2488165B1 (en) | 2009-10-14 | 2010-10-12 | Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy |
| PCT/IB2010/054618 WO2011045747A1 (en) | 2009-10-14 | 2010-10-12 | Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2009A000782A IT1397011B1 (it) | 2009-10-14 | 2009-10-14 | Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITTO20090782A1 ITTO20090782A1 (it) | 2011-04-15 |
| IT1397011B1 true IT1397011B1 (it) | 2012-12-20 |
Family
ID=42098064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITTO2009A000782A IT1397011B1 (it) | 2009-10-14 | 2009-10-14 | Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2488165B1 (it) |
| IT (1) | IT1397011B1 (it) |
| WO (1) | WO2011045747A1 (it) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3808845A1 (en) | 2004-06-28 | 2021-04-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| DK2499249T3 (en) | 2009-11-12 | 2018-12-03 | Univ Western Australia | ANTISENCE MOLECULES AND PROCEDURES FOR TREATING PATHOLOGIES |
| AU2014236140B2 (en) | 2013-03-14 | 2019-10-03 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| WO2014144978A2 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| JP2024505151A (ja) * | 2021-01-12 | 2024-02-05 | ノースウェスタン ユニバーシティ | 脂質ナノ粒子球状核酸 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2407501A (en) * | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell |
-
2009
- 2009-10-14 IT ITTO2009A000782A patent/IT1397011B1/it active
-
2010
- 2010-10-12 EP EP10771208.5A patent/EP2488165B1/en not_active Not-in-force
- 2010-10-12 WO PCT/IB2010/054618 patent/WO2011045747A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ITTO20090782A1 (it) | 2011-04-15 |
| EP2488165B1 (en) | 2014-07-23 |
| EP2488165A1 (en) | 2012-08-22 |
| WO2011045747A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | pH-sensitive nano-systems for drug delivery in cancer therapy | |
| IL232251B (en) | Pharmaceutical combination for use in the treatment of type 2 diabetes patients | |
| LT2170396T (lt) | Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui | |
| GB0715087D0 (en) | Drug combinations for the treatment of duchenne muscular dystrophy | |
| EP2391419A4 (en) | ACTIVE INFUSION IN THE REAR EYE SEGMENT | |
| IL236504A0 (en) | Oligonucleotide for the treatment of muscular dystrophy patients | |
| IL255752B (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer | |
| IT1397011B1 (it) | Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne. | |
| HUE044384T2 (hu) | Ultrafinom nanorészecskék, melyek egy fémkomplexeket tartalmazó funkcionalizált poliorganosziloxán mátrixot tartalmaznak; eljárás azok elõállítására, és alkalmazásuk gyógyászati képalkotásban | |
| EP2611421A4 (en) | TUMOR PLAYING OF A MEDICINAL PRODUCT ON NANOPARTICLE BASIS | |
| ITTO20110628A1 (it) | Composizione farmaceutica di combinazione e metodi per trattare patologie funzionali o stati patologici del tratto gastrointestinale | |
| EP2509421A4 (en) | ACTIVE COMPOSITION OF TEMOZOLOMIDE FOR SYSTEMIC CANCER TREATMENT | |
| LT4104824T (lt) | Kompozicijos, skirtos panaudoti taikant pacientams su didele širdies ir kraujagyslių ligos rizika antsvorio ir nutukimo gydymo būdą | |
| CL2012003340A1 (es) | Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras. | |
| BRPI1008517A2 (pt) | direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas. | |
| IT1403293B1 (it) | Apparecchiatura ad aghi per la somministrazione transdermica di farmaci. | |
| GB201511770D0 (en) | Novel pharmaceutical formulationsand their use in the treatment of periodontal disease | |
| DOP2011000031A (es) | Vacuna contra el virus del papiloma humano(hpv) | |
| EP2473039A4 (en) | PERMANENT TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINISATION | |
| ITTO20090487A1 (it) | Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd) | |
| EP2453742A4 (en) | IBUPROFEN TREATMENT INTRAVENOUSLY | |
| EP2632939A4 (en) | CANCER-TREATED PEPTIDES AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | |
| WO2011079213A9 (en) | Treating critically ill patients with intravenous ibuprofen | |
| LT2702033T (lt) | 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme | |
| FR2943671B1 (fr) | Composes anticancereux,leur preparation et leur application en therapeutique |